4494-84-2

Upstream product

• 100189-84-2 2,5-dibromo-1,3-dimethylbenzene 
• 106-95-6 allyl bromide 
• 74248-47-8 N-allyl-2,6-dimethylaniline 
• 4494-83-1 4-allyl-2,6-dimethylaniline 
• 87-62-7 2,6-dimethylaniline 

Downstream Products

• 1458654-29-9 3-(4-bromo-3,5-dimethylphenyl)propanal 
• 1458654-30-2 4-(4-bromo-3,5-dimethylphenyl)butan-2-ol 
• 1458654-31-3 4-(4-bromo-3,5-dimethylphenyl)butan-2-one 
• 1458654-33-5 4-(4-bromo-3,5-dimethylphenyl)-2-methylbutan-2-ol 
• 1458654-38-0 3-(4-bromo-3,5-dimethylphenyl)propyl methanesulfonate 
• 1458654-39-1 (3-(4-bromo-3,5-dimethylphenyl)propyl)(methyl)sulfane 
• 1458654-46-0 2-(4-bromo-3,5-dimethylphenyl)ethanol 
• 1458654-48-2 N,N-di-tert.-butoxycarbonyl-2-(4-bromo-3,5-dimethylphenyl)ethanamine 
• 1458654-50-6 tert-butyl 4-bromo-3,5-dimethylphenethylcarbamate 
• 1458654-28-8 3-(4-bromo-3,5-dimethylphenyl)propan-1-ol 

Relevant academic research and scientific papers

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS

The present invention relates to compounds of general formula I, (I), wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.